OSE Immunotherapeutics Receives New Approval for an Early Access Program for Tedopi® in Spain in Non-Small Cell Lung Cancer
OSE Immunotherapeutics SA has announced that the Spanish Drug Agency (Agencia Espanola de Medicamentos y Productos Sanitarios, AEMPS) has made available a new early access program that will allow access to Tedopi through a Special Situation Authorization in the treatment of advanced or metastatic non-small cell lung (NSCLC) after immune checkpoint inhibitor (ICI) failure. This Special Situation Authorization is based on the positive clinical data from the initial phase 3 trial of Tedopi (ATALANTE-1) in third line treatment and the high unmet need for these patients.
Tedopi® is the first cancer vaccine to show positive and clinically meaningful efficacy results with significant gain in survival associated with a better safety and quality of life profile in advanced NSCLC patients, administered in monotherapy versus active comparator (chemotherapy-based standard of care), in third line with secondary resistance to immune checkpoint inhibitor (ICI). OSE Immunotherapeutics is committed to provide Tedopi® through early access and compassionate use programs across European countries to address patients’ needs alongside physicians’ engagement. Patients can benefit from Tedopi® through compassionate use programs in third or further lines of treatment (post chemotherapy and immunotherapy) currently approved in France and Italy.
In Spain, following the earlier nominative compassionate use program for patients that were included in the phase 3 ATALANTE-1 trial, the Health Authorities are now expecting applications for the early access to Tedopi® through an unlimited Special Situation program, confirming thereby the significant medical need for new therapeutic alternatives in this patient population.
Dr. Santiago Viteri, investigator in ATALANTE-1 study and Medical Director of UOMI Cancer Center, Clinica Mi Tres Torres, Barcelona, comments, “The decision of the Spanish Health Agency to approve Tedopi® under a Special Situation Authorization for use will facilitate early access to treatment until Marketing Authorization and represent a significant benefit for patients in third line in secondary resistance post-sequential chemotherapy and immunotherapy. Indeed, there is a high unmet need for these patients as there are no therapeutic options yet approved after failure to immunotherapies and last resort chemotherapies are associated with multiple side effects and a poor quality of life.”
Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, comments: “Following the positive recommendations from the US Food and Drug Administration (FDA) “Type C” meeting and the European Medicines Agency (EMA) scientific advice, OSE Immunotherapeutics is continuing the clinical development for Tedopi in second line treatment to support its regulatory registration in secondary resistance to immunotherapy. We are preparing a new confirmatory phase 3 clinical trial versus standard of care for HLA-A2+ patients in advanced in non-small cell lung cancer (NSCLC).”
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more